Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022.
Journal: Pharmaceutical medicine
Published: September 09, 2025
Evolution and Breakthroughs in Exon Skipping and Splice Modulation: From Inception to Clinical Success.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 28, 2025
Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis.
Journal: Journal of comparative effectiveness research
Published: July 18, 2025
Givinostat (Duvyzat) for Duchenne muscular dystrophy.
Journal: The Medical letter on drugs and therapeutics
Published: January 06, 2025
Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 04, 2025
Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims Analysis.
Journal: Advances in therapy
Published: August 28, 2024
Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: June 18, 2024
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: June 04, 2024
Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy.
Journal: Biomedicines
Published: March 11, 2024
Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study.
Journal: Journal of neuromuscular diseases
Published: March 10, 2024
Last Updated: 10/31/2025